PELZIMRO
Live / Allowed — Approved for publication (as of 01 Apr 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 18 Sept 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99400375
- Mark type
- Stylized text
- Filed
- 18 Sept 2025
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
Owner
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 01 Apr 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 27 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 28 Jan 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 28 Jan 2026 — NON-FINAL ACTION E-MAILED
- 28 Jan 2026 — NON-FINAL ACTION WRITTEN
- 28 Jan 2026 — ASSIGNED TO EXAMINER
- 18 Sept 2025 — APPLICATION FILING RECEIPT MAILED
- 18 Sept 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 18 Sept 2025 — NEW APPLICATION ENTERED